AR093184A1 - Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden - Google Patents
Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprendenInfo
- Publication number
- AR093184A1 AR093184A1 ARP120102753A ARP120102753A AR093184A1 AR 093184 A1 AR093184 A1 AR 093184A1 AR P120102753 A ARP120102753 A AR P120102753A AR P120102753 A ARP120102753 A AR P120102753A AR 093184 A1 AR093184 A1 AR 093184A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- hydrogen
- inhibitor
- halo
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Abstract
Reivindicación 1: Un compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa, caracterizado porque se selecciona de los compuestos de la fórmula (1) y sus sales y profármacos farmacéuticamente aceptables, en la que: R¹ se selecciona de arilo opcionalmente sustituido y heteroarilo opcionalmente sustituido; R² se selecciona de ciano, heteroarilo opcionalmente sustituido y heterocicloalquilo opcionalmente sustituido; R³ se selecciona de hidrógeno y alquilo inferior opcionalmente sustituido; y R⁴ se selecciona de hidrógeno, halo, alquilo inferior opcionalmente sustituido, hidroxilo, alcoxi inferior opcionalmente sustituido, y amino opcionalmente sustituido, o R¹ y R⁴, tomados junto con los átomos a los que se unen forman un anillo bicíclico de la fórmula (2) que está opcionalmente sustituido en el que m es 0 ó 1 y n es 0 ó 1, con la condición de que al menos uno de m y n es 1, con la condición de que: i) cuando R² es 4-metiloxazol-2-ilo, R³ es metilo, y R⁴ es hidrógeno, entonces R¹ no es 3,4-diclorofenilo; y ii) cuando R³ y R⁴ son hidrógeno, entonces R¹ no es 5-cloropiridin-3-ilo, 3,5-diclorofenilo, o el resto de fórmula (3) donde R²¹ es halo y R²² es hidrógeno, halo, trifluorometoxi, metilo, o isopropoxi.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161512782P | 2011-07-28 | 2011-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR093184A1 true AR093184A1 (es) | 2015-05-27 |
Family
ID=47601528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120102753A AR093184A1 (es) | 2011-07-28 | 2012-07-27 | Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden |
Country Status (16)
Country | Link |
---|---|
US (2) | US9260422B2 (es) |
EP (1) | EP2736337A4 (es) |
JP (1) | JP2014521651A (es) |
KR (1) | KR20140082633A (es) |
CN (1) | CN103841829A (es) |
AR (1) | AR093184A1 (es) |
AU (1) | AU2012286851A1 (es) |
BR (1) | BR112014001991A2 (es) |
CA (1) | CA2841981A1 (es) |
EA (1) | EA201490163A1 (es) |
HK (1) | HK1198619A1 (es) |
IL (1) | IL230705A0 (es) |
MX (1) | MX2014001088A (es) |
TW (1) | TW201319056A (es) |
WO (1) | WO2013016488A1 (es) |
ZA (1) | ZA201400443B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0916576A2 (pt) | 2008-08-04 | 2017-06-27 | Chdi Inc | pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio. |
US9260422B2 (en) * | 2011-07-28 | 2016-02-16 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
EP3243515B1 (en) * | 2011-08-30 | 2019-10-16 | CHDI Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
WO2013033068A1 (en) | 2011-08-30 | 2013-03-07 | Stephen Martin Courtney | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
GB201322512D0 (en) | 2013-12-19 | 2014-02-05 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
EP3169684B1 (en) | 2014-07-17 | 2019-06-26 | CHDI Foundation, Inc. | Combination of kmo inhibitor 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid with antiviral agent for treating hiv related neurological disorders |
GB201508864D0 (en) | 2015-05-22 | 2015-07-01 | Glaxosmithkline Ip Dev Ltd | Compounds |
GB201508857D0 (en) | 2015-05-22 | 2015-07-01 | Glaxosmithkline Ip Dev Ltd | Compounds |
JP2019533676A (ja) | 2016-10-13 | 2019-11-21 | ジュノー セラピューティクス インコーポレイテッド | トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物 |
WO2018220762A1 (ja) * | 2017-05-31 | 2018-12-06 | 大塚製薬株式会社 | ピリミジン化合物 |
JP6965083B2 (ja) * | 2017-10-04 | 2021-11-10 | 公益財団法人微生物化学研究会 | 化合物、及び発光化合物 |
WO2019193516A2 (en) * | 2018-04-04 | 2019-10-10 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as glun2b receptor modulators |
KR102176621B1 (ko) * | 2018-08-21 | 2020-11-10 | 가천대학교 산학협력단 | 페닐피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 글루카곤 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
BR112021006222A2 (pt) | 2018-11-30 | 2021-07-06 | Otsuka Pharma Co Ltd | compostos heterocíclicos para o tratamento de epilepsia |
JP6870064B2 (ja) * | 2018-11-30 | 2021-05-12 | 大塚製薬株式会社 | ピリミジン化合物の医薬用途 |
US11911376B2 (en) | 2020-03-30 | 2024-02-27 | The Regents Of The University Of Colorado | Methods for preventing and treating retinal damage |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3908012A (en) * | 1970-10-05 | 1975-09-23 | Pfizer | Arylpyrimidines-inhibitors of platelet aggregation and bronchodilators |
US3950525A (en) * | 1973-06-19 | 1976-04-13 | Pfizer Inc. | Relaxation of smooth muscle in a mammal |
AU2004224392A1 (en) * | 2003-03-24 | 2004-10-07 | Merck & Co., Inc. | Biaryl substituted 6-membered heterocyles as sodium channel blockers |
WO2007037543A1 (ja) * | 2005-09-29 | 2007-04-05 | Banyu Pharmaceutical Co., Ltd. | ビアリールアミド誘導体 |
US8735411B2 (en) * | 2006-10-02 | 2014-05-27 | Abbvie Inc. | Macrocyclic benzofused pyrimidine derivatives |
KR20090065548A (ko) * | 2006-10-12 | 2009-06-22 | 노파르티스 아게 | Iap 억제제로서의 피롤리딘 유도체 |
US20090163508A1 (en) * | 2007-10-10 | 2009-06-25 | Takeda Pharmaceutical Company Limited | Amide compound |
US20110230428A1 (en) * | 2008-07-22 | 2011-09-22 | John Wityak | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
BRPI0916576A2 (pt) * | 2008-08-04 | 2017-06-27 | Chdi Inc | pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio. |
US20120041009A1 (en) * | 2009-05-18 | 2012-02-16 | Sumitomo Chemical Company, Limited | Pyrimidine compound and its use in pest control |
WO2011091153A1 (en) * | 2010-01-25 | 2011-07-28 | Chdi, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
US9260422B2 (en) * | 2011-07-28 | 2016-02-16 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
WO2013033068A1 (en) * | 2011-08-30 | 2013-03-07 | Stephen Martin Courtney | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
-
2012
- 2012-07-26 US US14/235,253 patent/US9260422B2/en active Active
- 2012-07-26 BR BR112014001991A patent/BR112014001991A2/pt not_active IP Right Cessation
- 2012-07-26 MX MX2014001088A patent/MX2014001088A/es unknown
- 2012-07-26 EP EP12817789.6A patent/EP2736337A4/en not_active Withdrawn
- 2012-07-26 KR KR1020147002297A patent/KR20140082633A/ko not_active Application Discontinuation
- 2012-07-26 JP JP2014522984A patent/JP2014521651A/ja active Pending
- 2012-07-26 CA CA2841981A patent/CA2841981A1/en not_active Abandoned
- 2012-07-26 WO PCT/US2012/048254 patent/WO2013016488A1/en active Application Filing
- 2012-07-26 AU AU2012286851A patent/AU2012286851A1/en not_active Abandoned
- 2012-07-26 CN CN201280037734.6A patent/CN103841829A/zh active Pending
- 2012-07-26 EA EA201490163A patent/EA201490163A1/ru unknown
- 2012-07-27 TW TW101127170A patent/TW201319056A/zh unknown
- 2012-07-27 AR ARP120102753A patent/AR093184A1/es unknown
-
2014
- 2014-01-20 ZA ZA2014/00443A patent/ZA201400443B/en unknown
- 2014-01-28 IL IL230705A patent/IL230705A0/en unknown
- 2014-12-01 HK HK14112101.5A patent/HK1198619A1/xx unknown
-
2016
- 2016-02-12 US US15/042,964 patent/US9649310B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2014001088A (es) | 2015-03-19 |
JP2014521651A (ja) | 2014-08-28 |
CN103841829A (zh) | 2014-06-04 |
WO2013016488A1 (en) | 2013-01-31 |
EP2736337A4 (en) | 2014-12-17 |
US9260422B2 (en) | 2016-02-16 |
HK1198619A1 (en) | 2015-05-22 |
AU2012286851A1 (en) | 2014-02-20 |
US20140329816A1 (en) | 2014-11-06 |
US20160361312A1 (en) | 2016-12-15 |
IL230705A0 (en) | 2014-03-31 |
EP2736337A1 (en) | 2014-06-04 |
AU2012286851A8 (en) | 2014-04-03 |
CA2841981A1 (en) | 2013-01-31 |
TW201319056A (zh) | 2013-05-16 |
EA201490163A1 (ru) | 2014-06-30 |
KR20140082633A (ko) | 2014-07-02 |
BR112014001991A2 (pt) | 2017-02-21 |
ZA201400443B (en) | 2016-07-27 |
US9649310B2 (en) | 2017-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR093184A1 (es) | Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden | |
CY1120188T1 (el) | ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6 | |
CR20130369A (es) | Novedosos derivados heterocíclicos | |
CY1119345T1 (el) | Μακροκυκλικες ενωσεις ως αναστολεις κινασης trk | |
CR20160098A (es) | Polimorfo de los inhibidores de la syk | |
CR20200276A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059) | |
CR20140042A (es) | Indazoles | |
UY34825A (es) | Síntesis de compuestos heterocíclicos | |
CR20130537A (es) | Compuestos heterocíclicos como inhibidores de cinasas | |
CR20140510A (es) | Nucleósidos de espirooxetano de uracilo | |
CR20130470A (es) | INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [2,3-d]PIRIMIDINA TROMPOMIOSINA | |
ECSP11010912A (es) | Compuestos de pirrol | |
PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
IN2014MN02496A (es) | ||
CR20150061A (es) | Compuesto de pirazolopirimidinas | |
CR20120417A (es) | Inhibidores de virus flaviviridae | |
MX2013012760A (es) | Nuevos compuestos y composiciones para la inhibicion de nampt. | |
PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
CR20130233A (es) | Derivados que quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinaza | |
CR20150663A (es) | Derivados de diazacarbazol como ligandos de tau para pet | |
IN2013MN02014A (es) | ||
CR20130419A (es) | Derivados heterocíclicos de amina | |
EA201691031A1 (ru) | Синтез макроциклического трипептида, ингибирующего hcv ns3 | |
CR20130501A (es) | Derivados novedosos de cefalosporinas y composiciones farmacéuticas de estos | |
ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |